Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

A polymorphism linked to elevated levels of interferon-γ is associated with an increased risk of cytomegalovirus disease among Caucasian lung transplant recipients at a single center.

Mitsani D, Nguyen MH, Girnita DM, Spichty K, Kwak EJ, Silveira FP, Toyoda Y, Pilewski JM, Crespo M, Bhama JK, Abdel-Massih R, Zaldonis D, Zeevi A, Clancy CJ.

J Heart Lung Transplant. 2011 May;30(5):523-9. doi: 10.1016/j.healun.2010.11.008. Epub 2011 Jan 15.

PMID:
21239188
2.

Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.

Mitsani D, Nguyen MH, Kwak EJ, Silveira FP, Vadnerkar A, Pilewski J, Crespo M, Toyoda Y, Bermudez C, Clancy CJ.

J Heart Lung Transplant. 2010 Sep;29(9):1014-20. doi: 10.1016/j.healun.2010.04.022. Epub 2010 Jul 3.

PMID:
20598582
3.

Interferon-gamma gene polymorphism +874 A/T is associated with an increased risk of cytomegalovirus infection among Hispanic renal transplant recipients.

Vu D, Shah T, Ansari J, Sakharkar P, Yasir Q, Naraghi R, Hutchinson I, Min D.

Transpl Infect Dis. 2014 Oct;16(5):724-32. doi: 10.1111/tid.12285. Epub 2014 Sep 11.

PMID:
25208755
4.

Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.

Wiita AP, Roubinian N, Khan Y, Chin-Hong PV, Singer JP, Golden JA, Miller S.

Transpl Infect Dis. 2012 Jun;14(3):248-58. doi: 10.1111/j.1399-3062.2012.00723.x. Epub 2012 Mar 5.

5.

Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.

Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK.

Pharmacotherapy. 2004 Oct;24(10):1323-30.

PMID:
15628830
6.

Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus.

Gruber SA, Garnick J, Morawski K, Sillix DH, West MS, Granger DK, El-Amm JM, Alangaden GJ, Chandrasekar P, Haririan A.

Clin Transplant. 2005 Apr;19(2):273-8.

PMID:
15740567
7.

Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.

Cervera C, Pineda M, Linares L, Marcos MA, Esteva C, Antón A, Cofán F, Ricart MJ, Navasa M, Pérez-Villa F, Pumarola T, Moreno A.

Transplant Proc. 2007 Sep;39(7):2228-30.

PMID:
17889146
8.

Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.

Luan FL, Samaniego M, Kommareddi M, Park JM, Ojo AO.

Transpl Infect Dis. 2010 Dec;12(6):473-9. doi: 10.1111/j.1399-3062.2010.00532.x.

9.

Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.

Kuo HT, Ye X, Sampaio MS, Reddy P, Bunnapradist S.

Transplantation. 2010 Nov 27;90(10):1091-8. doi: 10.1097/TP.0b013e3181f7c053.

PMID:
20885340
10.

A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients.

Humar A, Kumar D, Preiksaitis J, Boivin G, Siegal D, Fenton J, Jackson K, Nia S, Lien D.

Am J Transplant. 2005 Jun;5(6):1462-8.

11.

Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients.

Johansson I, Mårtensson G, Nyström U, Nasic S, Andersson R.

BMC Infect Dis. 2013 Dec 10;13:582. doi: 10.1186/1471-2334-13-582.

12.

[Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].

Kılınçkaya Doğan H, Mutlu E, Köksoy S, Yılmaz VT, Koçak H, Çolak D, Mutlu D, Günseren F, Dinçkan A, Aliosmanoğlu İ, Süleymanlar G, Gültekin M.

Mikrobiyol Bul. 2016 Apr;50(2):224-35. Turkish.

13.

Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience.

Lopez Garcia-Gallo C, García Fadul C, Laporta R, Portero F, Millan I, Ussetti P.

Ann Transplant. 2015 Nov 5;20:661-6.

14.

Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation.

Ranganathan K, Worley S, Michaels MG, Arrigan S, Aurora P, Ballmann M, Boyer D, Conrad C, Eichler I, Elidemir O, Goldfarb S, Mallory GB Jr, Mogayzel PJ, Parakininkas D, Solomon M, Visner G, Sweet SC, Faro A, Danziger-Isakov L.

J Heart Lung Transplant. 2009 Oct;28(10):1050-6. doi: 10.1016/j.healun.2009.04.032.

15.

Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy.

Jaksch P, Zweytick B, Kerschner H, Hoda AM, Keplinger M, Lang G, Aigner C, Klepetko W.

J Heart Lung Transplant. 2009 Jul;28(7):670-5. doi: 10.1016/j.healun.2009.03.012. Epub 2009 May 13.

PMID:
19560694
16.

Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.

Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark J.

Transpl Infect Dis. 2015 Apr;17(2):163-73. doi: 10.1111/tid.12349. Epub 2015 Feb 6.

PMID:
25661673
17.

Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?

Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A.

Transplant Proc. 2005 Sep;37(7):3182-6.

PMID:
16213344
18.

[Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].

Torre-Cisneros J, Caston-Osorio JJ, Martín C, Rivero A, Doblas A, Rojas R, Gómez P, Martínez F, Torres A.

Enferm Infecc Microbiol Clin. 2010 Jan;28(1):6-12. doi: 10.1016/j.eimc.2009.01.010. Epub 2009 May 1. Spanish.

PMID:
19409666
19.

Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.

Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M; VIPP Study Group..

Transplantation. 2012 Jan 15;93(1):61-8. doi: 10.1097/TP.0b013e318238dab3.

PMID:
22094954
20.

Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.

Minces LR, Nguyen MH, Mitsani D, Shields RK, Kwak EJ, Silveira FP, Abdel-Massih R, Pilewski JM, Crespo MM, Bermudez C, Bhama JK, Toyoda Y, Clancy CJ.

Antimicrob Agents Chemother. 2014;58(1):128-35. doi: 10.1128/AAC.00561-13. Epub 2013 Oct 21.

Supplemental Content

Support Center